Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DualStim Therapy + umbilical cord-derived Wharton's Jelly is a therapeutic combination specifically evaluated for the treatment of moderate to severe erectile dysfunction. DualStim Therapy employs a combination of *focused* and *radial low-intensity extracorporeal shock wave therapy (ESWT)*, aiming to stimulate angiogenesis and tissue regeneration in the corpora cavernosa. This is paired with *intracavernosal injection* of a formulated preparation of Wharton’s Jelly derived from human umbilical cord tissue, which is rich in mesenchymal stem cells, growth factors, cytokines, hyaluronic acid, extracellular vesicles, collagen, and sulfated proteoglycans. The stem cells and bioactive components of Wharton’s Jelly are hypothesized to promote tissue repair, modulate inflammation, and enhance vascularization in penile tissues to restore erectile function. This combination aims for potential synergistic effects between mechanical stimulation (by ESWT) and the regenerative properties of the biologic product[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DualStim Therapy + umbilical cord-derived Wharton's Jelly.